Reactogenicity and Immunogenicity of Vaginal CNgp140

Phase 1 Terminated 23 enrolled St George's, University of London Bill and Melinda Gates Foundation · collab York Hospitals · collab

RandomizedParallel-groupTriple-blindPrevention

Summary

To determine the local (cervico-vaginal) and systemic (whole body) safety of vaginal immunisation with CN54gp140 glycoprotein administered 9 times over a 3 week period.

Timeline

Start: 2007-09
Primary completion: 2008-10
Completion: 2009-01

Publications

Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, Cope A, Cai C, Giemza R, Jeffs SA, Manoussaka M, Cole T, Cranage MP, Shattock RJ, Lacey CJ. Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS One. 2011;6(9):e25165. doi: 10.1371/journal.pone.0025165. Epub 2011 Sep 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CN54gp140	Vaccine	100 ug	Other

Reactogenicity and Immunogenicity of Vaginal CNgp140

Summary

Timeline

Publications

Drugs

Indications